{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:27:31Z","timestamp":1788715651845,"version":"build-2803163510"},"reference-count":49,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Int AIDS Soc."],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Despite increasingly widespread acceptance of the (undetectable = untransmittable) U = U concept, uncertainty remains about the implications of suppressed viral loads (detected but \u22641000 copies\/ml, also often referred to as low\u2010level viraemia) for both sexual HIV transmission and individual patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      There has been no documented evidence of a transmission event when the index partner had a viral load &lt;200 copies\/ml, suggesting zero risk of sexual transmission. Additionally, the risk of sexual transmission when the index partner is taking medication as prescribed and has a viral load that is detectable but suppressed (\n                      <jats:italic>\u2264<\/jats:italic>\n                      1000 copies\/ml) is negligible. The clinical implications, including drug resistance development, of persistent low\u2010level viraemia in people with HIV (PWH) taking dolutegravir\u2010containing antiretroviral therapy remains limited and relatively unknown; ongoing research and surveillance will be critical to monitor expanded scale\u2010up of optimized treatment. To support widespread access to treatment monitoring for all PWH, viral load testing should be expanded using any combination of available viral load technologies and sample types, as they can all support the primary objectives of understanding the viral load of PWH, for both prevention and treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PWH who have an undetectable or suppressed viral load should be celebrated and encouraged to maintain their treatment adherence and engagement in care, while ensuring that no remaining barriers exist for them to do so.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jia2.70085","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T10:29:45Z","timestamp":1772965785000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["HIV low\u2010level viraemia: considerations for prevention and treatment in an era of highly effective and durable antiretroviral therapy regimens"],"prefix":"10.1002","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0488-1012","authenticated-orcid":false,"given":"Lara","family":"Vojnov","sequence":"first","affiliation":[{"name":"Global Health Impact Group  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0755-4386","authenticated-orcid":false,"given":"Linda\u2010Gail","family":"Bekker","sequence":"additional","affiliation":[{"name":"Desmond Tutu HIV Centre Department of Medicine University of Cape Town  Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5917-9664","authenticated-orcid":false,"given":"Myron S.","family":"Cohen","sequence":"additional","affiliation":[{"name":"University of North Carolina (UNC) at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Jahn","sequence":"additional","affiliation":[{"name":"Department of HIV AIDS Ministry of Health  Lilongwe Malawi"},{"name":"International Training and Education Center for Health Department for Global Health University of Washington  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0761-3136","authenticated-orcid":false,"given":"Diane","family":"Havlir","sequence":"additional","affiliation":[{"name":"Division of HIV ID and Global Medicine Department of Medicine University of California San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9850-3479","authenticated-orcid":false,"given":"Debrah","family":"Boeras","sequence":"additional","affiliation":[{"name":"Global Health Impact Group  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1482-3967","authenticated-orcid":false,"given":"Nathan","family":"Ford","sequence":"additional","affiliation":[{"name":"World Health Organization  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagalingesawaran","family":"Kumarasamy","sequence":"additional","affiliation":[{"name":"CART CRS Voluntary Health Services  Chennai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura N.","family":"Broyles","sequence":"additional","affiliation":[{"name":"Global Health Impact Group  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"i\u2010base.The evidence for U = U (Undetectable = Untransmittable): why negligible risk is zero.2017(https:\/\/i\u2010base.info\/htb\/32308 accessed 25 Sept 2023)."},{"key":"e_1_2_6_3_1","unstructured":"The Center for HIV Law & Policy.HIV criminalization in the United States: a sourcebook on state and federal HIV criminal law and practice.2022(https:\/\/www.hivlawandpolicy.org\/sites\/default\/files\/HIV%20Criminalization%20in%20the%20U.S.%20A%20Sourcebook%20on%20State%20Fed%20HIV%20Criminal%20Law%20and%20Practice%20022722.pdf accessed 15 Jan 2025)."},{"key":"e_1_2_6_4_1","volume-title":"The role of HIV viral suppression in improving individual health and reducing transmission","year":"2023"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30132-2"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.5148"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30418-0"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1600693"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003303421303"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001888"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00877-2"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/088922201750290023"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001019"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa270"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab541"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0003030"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30681-3"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279479"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac762"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26316"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26200"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12756"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11102927"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102166"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae569"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001678"},{"key":"e_1_2_6_27_1","unstructured":"UNAIDS Global AIDS Monitoring.2023. (https:\/\/www.unaids.org\/en\/resources\/documents\/2022\/global\u2010aids\u2010monitoring\u2010guidelines accessed 25 Sept 2022)."},{"key":"e_1_2_6_28_1","unstructured":"Clinton Health Access Initiative.2024 HIV Market Report. Issue 15 December 2024. (https:\/\/www.clintonhealthaccess.org\/wp\u2010content\/uploads\/2024\/12\/2024\u2010HIV\u2010Market\u2010Report_12.20.24.pdf accessed 24 Jan 2025)."},{"key":"e_1_2_6_29_1","unstructured":"UNAIDS.How the shift in US funding is threatening both the lives of people affected by HIV and the community groups supporting them.2025. (https:\/\/www.unaids.org\/en\/resources\/presscentre\/featurestories\/2025\/february\/20250218_us\u2010funding\u2010people\u2010affected\u2010hiv\u2010community\u2010groups accessed 24 Mar 2025)."},{"key":"e_1_2_6_30_1","unstructured":"World Health Organization.HIV drug resistance report.2021. (https:\/\/www.who.int\/publications\/i\/item\/9789240038608 accessed 12 Apr 2023)."},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac148"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad010"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08288-8"},{"key":"e_1_2_6_34_1","unstructured":"World Health Organization.HIV drug resistance\u2014brief report.2024. (https:\/\/www.who.int\/publications\/i\/item\/9789240086319 accessed 2 Dec 2024)."},{"key":"e_1_2_6_35_1","unstructured":"SkrivankovaVW HuwaJ MuulaG ChiwayaGD BandaE BuleyaS et\u00a0al.Viremia and drug resistance over 2 years after routine switching to dolutegravir\u2010based first\u2010line ART.2024 Conference on Retroviruses and Opportunistic Infections.Denver Colorado. (https:\/\/www.croiconference.org\/wp\u2010content\/uploads\/sites\/2\/posters\/2024\/676.pdf accessed 2 Dec 2024)."},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2402088"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00289-5"},{"key":"e_1_2_6_38_1","unstructured":"WHO list of prequalified in vitro diagnostic products.Geneva:World Health Organization;2022(https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/documents\/220420_List_PQ_IVD_Products.pdf accessed 30 Jun 2022)."},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25663"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00118-2"},{"key":"e_1_2_6_41_1","unstructured":"HIV molecular diagnostics toolkit to improve access to viral load testing and infant diagnosis.Geneva:World Health Organization;2019(https:\/\/apps.who.int\/iris\/handle\/10665\/325961 accessed 25 Sept 2023)."},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004076"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002303"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2011.09.015"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00578-12"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219381"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00028-0"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25455"},{"key":"e_1_2_6_49_1","unstructured":"UNAIDS.Country fact sheets.2025. (https:\/\/www.unaids.org\/en\/regionscountries\/countries accessed 2 Apr 2025)."},{"key":"e_1_2_6_50_1","unstructured":"US Centers for Disease Control.Tracking PEPFAR impact towards global targets: PHIA survey data highlights.2025. (https:\/\/www.cdc.gov\/global\u2010hiv\u2010tb\/php\/data\/phia.html accessed 2 Apr 2025)."}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.70085","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jia2.70085","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.70085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T21:24:50Z","timestamp":1773005090000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.70085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/jia2.70085"],"URL":"https:\/\/doi.org\/10.1002\/jia2.70085","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70085"}}